Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 6/2018

01-06-2018 | Original Article

Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study

Authors: Chu-Wen Fang, Cheng-Hsi Liao, Shih-Chi Wu, Chih-Hsin Muo

Published in: World Journal of Urology | Issue 6/2018

Login to get access

Abstract

Objectives

Few studies discussed the link between benign prostatic hyperplasia (BPH) and bladder cancer. We performed this cohort study to investigate whether there is an association between BPH and subsequent risk of bladder cancer.

Methods

We identified 35,092 study subjects including 17546 BPH patients and 17546 comparisons from the National Health Insurance database. The comparison cohort was frequency matched with age and index-year. We measured subsequent bladder cancer rates (per 1000 person-years) in two cohorts. Attributable risks (ARs) was calculated based on the bladder cancer rates in two cohorts. The hazard ratios (HRs) and 95% confidence intervals (CIs) for bladder cancer were estimated via Cox proportional hazard regression.

Results

BPH patients had a higher bladder cancer rate than comparisons (AR = 0.81 per 1000 person-years) and exhibited 4.69- and 4.11-fold increases in bladder cancer risk in the crude and adjusted Cox models, respectively (95% CIs = 4.15–6.99 and 2.70–6.26). The AR was highest in patients aged 65–74 years old (AR = 1.33). BPH patients with chronic kidney disease were at an elevated bladder cancer risk. Regarding the association between bladder cancer and transurethral prostatectomy (TURP), BPH patients who underwent TURP were at a higher risk of bladder cancer (AR = 1.69; HR = 6.17, 95% CI = 3.68–10.3) than those who did not (AR = 0.69; HR = 3.73, 95% CI = 2.43–5.74).

Conclusions

In this study, BPH patients were found to have an increased risk of subsequent bladder cancer. Based on the limitations of retrospective nature, further studies are needed.
Literature
1.
Auffenberg GB, Helfand BT, McVary KT (2009) Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 36:443–459CrossRefPubMed
2.
Barry MJ, Fowler FJ Jr, Bin L et al (1997) The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157:10–14CrossRefPubMed
3.
Fong YK, Milani S, Djavan B (2005) Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 15:35–38CrossRefPubMed
4.
Djavan B, Nickel JC, de la Rosette J et al (2002) The urologist view of BPH progression: results of an international survey. Eur Urol 41(5):490–496CrossRefPubMed
5.
Sarma AV, Wei JT (2012) Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367(3):248–257CrossRefPubMed
6.
Matsumoto S, Shimizu N, Hanai T, Uemura H, Levin R (2009) Bladder outlet obstruction accelerates bladder carcinogenesis. BJU Int 103:1436–1439CrossRefPubMed
7.
Hecht SS (2002) Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23(6):907–922CrossRefPubMed
8.
Mommsen S, Sell A (1983) Prostatic hypertrophy and venereal disease as possible risk factors in the development of bladder cancer. Urol Res 11(2):49–52CrossRefPubMed
9.
Nakata S, Sato J, Ohtake N et al (1995) Epidemiological study of risk factors for bladder cancer. Hinyokika Kiyo 41(12):969–977PubMed
10.
Greenwald P, Kirmss V, Polan A et al (1974) Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst 53:335–340CrossRefPubMed
11.
12.
Tseng CH (2013) Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 13:7CrossRefPubMedPubMedCentral
13.
Dai X, Fang X, Ma Y et al (2016) Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies. Medicine (Baltim) 95(18):e3493CrossRef
14.
Lin YC, Liang SJ, Liu YH, Hsu WH, Shih CM, Sung FC, Chen W (2012) Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan. Rheumatol Int 32(6):1669–1673CrossRefPubMed
15.
Sung PS, Yeh CC, Wang LC, Hung PH, Muo CH, Sung FC, Chen CH, Tsai KJ (2017) Increased risk of dementia in patients with non-apnea sleep disorder. Curr Alzheimer Res 14(3):309–316PubMed
16.
Kang JH, Keller JJ, Lin YK, Lin HC (2012) A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. J Vasc Surg 56(6):1642–1648CrossRefPubMed
17.
Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54(8):2009–2015CrossRefPubMed
18.
Lo SF, Chang SN, Muo CH, Chen SY, Liao FY, Dee SW, Chen PC, Sung FC (2013) Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer 132(1):182–188CrossRefPubMed
19.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306(7):737–745CrossRefPubMedPubMedCentral
20.
Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241CrossRefPubMed
21.
Walker NF, Gan C, Olsburgh J et al (2014) Diagnosis and management of intradiverticular bladder tumours. Nat Rev Urol 11(7):383–390CrossRefPubMed
22.
Michaud DS, Spiegelman D, Clinton SK et al (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340:1390–1397CrossRefPubMed
23.
Jiang X, Castelao JE, Groshen S et al (2008) Water intake and bladder cancer risk in Los Angeles County. Int J Cancer 123:1649–1656CrossRefPubMed
24.
Radosavljević V, Janković S, Marinković J et al (2003) Fluid intake and bladder cancer. A case control study. Neoplasma 50(3):234–238PubMed
25.
26.
Altieri A, La Vecchia C, Negri E et al (2003) Fluid intake and risk of bladder and other cancers. Eur J Clin Nutr 57(Suppl 2):S59–S68CrossRefPubMed
27.
Zhou J, Smith S, Giovannucci E et al (2012) Reexamination of total fluid intake and bladder cancer in the health professionals follow-up study cohort. Am J Epidemiol 175(7):696–705CrossRefPubMedPubMedCentral
28.
29.
Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6(3):135–144CrossRefPubMedPubMedCentral
30.
Serrano M, Blasco MA (2007) Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 8:715–722CrossRefPubMed
31.
Toren Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448:767–774CrossRefPubMed
32.
33.
34.
35.
Blagosklonny MV (2005) Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 12(6):592–602CrossRefPubMed
36.
37.
Hou L, Zhang X, Wang D et al (2012) Environmental chemical exposures and human epigenetics. Int J Epidemiol 41(1):79–105CrossRefPubMed
38.
Wood GA, Korkola JE, Archer MC (2002) Tissue-specific resistance to cancer development in the rat: phenotypes of tumor-modifier genes. Carcinogenesis 23(1):1–9CrossRefPubMed
39.
Rassweiler J, Teber D, Kuntz R et al (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50(5):969–979CrossRefPubMed
40.
Yamasaki T, Naganuma T, Iguchi T et al (2011) Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia. Nephrology (Carlton) 16(3):335–339CrossRef
41.
Rule AD, Jacobson DJ, Roberts RO et al (2005) The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int 67(6):2376–2382CrossRefPubMed
42.
Chen CH, Shun CT, Huang KH, Huang CY, Yu HJ, Pu YS (2008) Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease. Urology. 71:1155–1160CrossRefPubMed
43.
Li CE, Chien CS, Chuang YC et al (2016) Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. Int Urol Nephrol. 48(6):993–999CrossRefPubMed
44.
Birkeland SA, Lokkegaard H, Storm HH (2000) Cancer risk in patients on dialysis and after renal transplantation. Lancet 355:1886–1887CrossRefPubMed
45.
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant. 4:905–913CrossRefPubMed
Metadata
Title
Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study
Authors
Chu-Wen Fang
Cheng-Hsi Liao
Shih-Chi Wu
Chih-Hsin Muo
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 6/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2216-8

Other articles of this Issue 6/2018

World Journal of Urology 6/2018 Go to the issue

Original Article

Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial

Original Article

Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study

Original Article

Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF–III renal cysts: a multicenter study

Original Article

Ureteroscopic holmium laser-assisted retrograde nephrostomy access: a novel approach to percutaneous stone removal

Original Article

Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding

Original Article

Modified York Mason technique for repair of iatrogenic recto-urinary fistula: 20 years of the Montsouris experience